Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
60
NVS Quote, Financials, Valuation and Earnings
Last price:
$154.00
Seasonality move
:
3.7%
Day range:
$153.16 - $154.81
52-week range:
$97.72 - $170.46
Dividend yield:
3.1%
P/E ratio:
21.44x
P/S ratio:
5.49x
P/B ratio:
6.37x
Volume:
2.6M
Avg. volume:
2.5M
1-year change:
39.05%
Market cap:
$291.9B
Revenue:
$54.8B
EPS (TTM):
$7.19
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
NVS
Novartis AG
|
$14.3B | $2.14 | 0.34% | 13.39% | $153.27 |
|
AMGN
Amgen, Inc.
|
$8.6B | $4.75 | 3.22% | 118.8% | $350.41 |
|
AZN
AstraZeneca PLC
|
$15.3B | $1.08 | 4.77% | 35.97% | $135.50 |
|
BIIB
Biogen, Inc.
|
$2.4B | $4.38 | -6.21% | 1.28% | $207.33 |
|
GILD
Gilead Sciences, Inc.
|
$7.4B | $2.10 | 4.17% | 82.62% | $157.43 |
|
RHHBY
Roche Holding AG
|
$19.8B | -- | -- | -- | $55.10 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
NVS
Novartis AG
|
$154.03 | $153.27 | $291.9B | 21.44x | $4.74 | 3.1% | 5.49x |
|
AMGN
Amgen, Inc.
|
$347.94 | $350.41 | $184.8B | 24.45x | $2.52 | 2.82% | 5.13x |
|
AZN
AstraZeneca PLC
|
$203.49 | $135.50 | $319.6B | 62.87x | $2.15 | 1.54% | 10.94x |
|
BIIB
Biogen, Inc.
|
$177.34 | $207.33 | $25.1B | 19.43x | $0.00 | 0% | 2.63x |
|
GILD
Gilead Sciences, Inc.
|
$139.71 | $157.43 | $172.7B | 20.51x | $0.82 | 2.29% | 5.93x |
|
RHHBY
Roche Holding AG
|
$49.85 | $55.10 | $314.1B | 20.52x | $1.59 | 3.23% | 4.27x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
NVS
Novartis AG
|
43.4% | 0.246 | 13.43% | 0.75x |
|
AMGN
Amgen, Inc.
|
86.49% | 0.240 | 32.2% | 0.74x |
|
AZN
AstraZeneca PLC
|
37.84% | -0.035 | 10.39% | 0.52x |
|
BIIB
Biogen, Inc.
|
26.72% | 0.729 | 25.77% | 1.70x |
|
GILD
Gilead Sciences, Inc.
|
52.94% | 0.640 | 16.78% | 1.23x |
|
RHHBY
Roche Holding AG
|
53.53% | 0.497 | -- | 0.88x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
NVS
Novartis AG
|
$9.8B | $3.5B | 18.52% | 32.47% | 26.4% | $1.2B |
|
AMGN
Amgen, Inc.
|
$8.1B | $3.9B | 11.96% | 102.03% | 39.83% | $961M |
|
AZN
AstraZeneca PLC
|
$11.2B | $2.9B | 13.53% | 23.12% | 18.93% | $1.1B |
|
BIIB
Biogen, Inc.
|
$1.5B | $372.1M | 5.34% | 7.36% | 17.06% | $401.7M |
|
GILD
Gilead Sciences, Inc.
|
$6.3B | $3B | 18.53% | 41.72% | 37.64% | $3.1B |
|
RHHBY
Roche Holding AG
|
-- | -- | 14.32% | 28.65% | -- | -- |
Novartis AG vs. Competitors
-
Which has Higher Returns NVS or AMGN?
Amgen, Inc. has a net margin of 18.03% compared to Novartis AG's net margin of 13.47%. Novartis AG's return on equity of 32.47% beat Amgen, Inc.'s return on equity of 102.03%.
Company Gross Margin Earnings Per Share Invested Capital NVSNovartis AG73.44% $1.25 $81.9B AMGNAmgen, Inc.81.91% $2.45 $64.1B -
What do Analysts Say About NVS or AMGN?
Novartis AG has a consensus price target of $153.27, signalling downside risk potential of -2.36%. On the other hand Amgen, Inc. has an analysts' consensus of $350.41 which suggests that it could grow by 0.75%. Given that Amgen, Inc. has higher upside potential than Novartis AG, analysts believe Amgen, Inc. is more attractive than Novartis AG.
Company Buy Ratings Hold Ratings Sell Ratings NVSNovartis AG2 5 2 AMGNAmgen, Inc.9 18 2 -
Is NVS or AMGN More Risky?
Novartis AG has a beta of 0.523, which suggesting that the stock is 47.695% less volatile than S&P 500. In comparison Amgen, Inc. has a beta of 0.471, suggesting its less volatile than the S&P 500 by 52.947%.
-
Which is a Better Dividend Stock NVS or AMGN?
Novartis AG has a quarterly dividend of $4.74 per share corresponding to a yield of 3.1%. Amgen, Inc. offers a yield of 2.82% to investors and pays a quarterly dividend of $2.52 per share. Novartis AG pays 42.5% of its earnings as a dividend. Amgen, Inc. pays out 66.92% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios NVS or AMGN?
Novartis AG quarterly revenues are $13.3B, which are larger than Amgen, Inc. quarterly revenues of $9.9B. Novartis AG's net income of $2.4B is higher than Amgen, Inc.'s net income of $1.3B. Notably, Novartis AG's price-to-earnings ratio is 21.44x while Amgen, Inc.'s PE ratio is 24.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 5.49x versus 5.13x for Amgen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NVSNovartis AG5.49x 21.44x $13.3B $2.4B AMGNAmgen, Inc.5.13x 24.45x $9.9B $1.3B
-
Which has Higher Returns NVS or AZN?
AstraZeneca PLC has a net margin of 18.03% compared to Novartis AG's net margin of 15.02%. Novartis AG's return on equity of 32.47% beat AstraZeneca PLC's return on equity of 23.12%.
Company Gross Margin Earnings Per Share Invested Capital NVSNovartis AG73.44% $1.25 $81.9B AZNAstraZeneca PLC72.19% $0.74 $78.3B -
What do Analysts Say About NVS or AZN?
Novartis AG has a consensus price target of $153.27, signalling downside risk potential of -2.36%. On the other hand AstraZeneca PLC has an analysts' consensus of $135.50 which suggests that it could fall by -57.25%. Given that AstraZeneca PLC has more downside risk than Novartis AG, analysts believe Novartis AG is more attractive than AstraZeneca PLC.
Company Buy Ratings Hold Ratings Sell Ratings NVSNovartis AG2 5 2 AZNAstraZeneca PLC1 0 0 -
Is NVS or AZN More Risky?
Novartis AG has a beta of 0.523, which suggesting that the stock is 47.695% less volatile than S&P 500. In comparison AstraZeneca PLC has a beta of 0.346, suggesting its less volatile than the S&P 500 by 65.388%.
-
Which is a Better Dividend Stock NVS or AZN?
Novartis AG has a quarterly dividend of $4.74 per share corresponding to a yield of 3.1%. AstraZeneca PLC offers a yield of 1.54% to investors and pays a quarterly dividend of $2.15 per share. Novartis AG pays 42.5% of its earnings as a dividend. AstraZeneca PLC pays out 15.28% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios NVS or AZN?
Novartis AG quarterly revenues are $13.3B, which are smaller than AstraZeneca PLC quarterly revenues of $15.5B. Novartis AG's net income of $2.4B is higher than AstraZeneca PLC's net income of $2.3B. Notably, Novartis AG's price-to-earnings ratio is 21.44x while AstraZeneca PLC's PE ratio is 62.87x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 5.49x versus 10.94x for AstraZeneca PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NVSNovartis AG5.49x 21.44x $13.3B $2.4B AZNAstraZeneca PLC10.94x 62.87x $15.5B $2.3B
-
Which has Higher Returns NVS or BIIB?
Biogen, Inc. has a net margin of 18.03% compared to Novartis AG's net margin of -2.24%. Novartis AG's return on equity of 32.47% beat Biogen, Inc.'s return on equity of 7.36%.
Company Gross Margin Earnings Per Share Invested Capital NVSNovartis AG73.44% $1.25 $81.9B BIIBBiogen, Inc.68.12% -$0.33 $24.9B -
What do Analysts Say About NVS or BIIB?
Novartis AG has a consensus price target of $153.27, signalling downside risk potential of -2.36%. On the other hand Biogen, Inc. has an analysts' consensus of $207.33 which suggests that it could grow by 16.74%. Given that Biogen, Inc. has higher upside potential than Novartis AG, analysts believe Biogen, Inc. is more attractive than Novartis AG.
Company Buy Ratings Hold Ratings Sell Ratings NVSNovartis AG2 5 2 BIIBBiogen, Inc.13 19 1 -
Is NVS or BIIB More Risky?
Novartis AG has a beta of 0.523, which suggesting that the stock is 47.695% less volatile than S&P 500. In comparison Biogen, Inc. has a beta of 0.162, suggesting its less volatile than the S&P 500 by 83.797%.
-
Which is a Better Dividend Stock NVS or BIIB?
Novartis AG has a quarterly dividend of $4.74 per share corresponding to a yield of 3.1%. Biogen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novartis AG pays 42.5% of its earnings as a dividend. Biogen, Inc. pays out -- of its earnings as a dividend. Novartis AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios NVS or BIIB?
Novartis AG quarterly revenues are $13.3B, which are larger than Biogen, Inc. quarterly revenues of $2.2B. Novartis AG's net income of $2.4B is higher than Biogen, Inc.'s net income of -$48.9M. Notably, Novartis AG's price-to-earnings ratio is 21.44x while Biogen, Inc.'s PE ratio is 19.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 5.49x versus 2.63x for Biogen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NVSNovartis AG5.49x 21.44x $13.3B $2.4B BIIBBiogen, Inc.2.63x 19.43x $2.2B -$48.9M
-
Which has Higher Returns NVS or GILD?
Gilead Sciences, Inc. has a net margin of 18.03% compared to Novartis AG's net margin of 27.44%. Novartis AG's return on equity of 32.47% beat Gilead Sciences, Inc.'s return on equity of 41.72%.
Company Gross Margin Earnings Per Share Invested Capital NVSNovartis AG73.44% $1.25 $81.9B GILDGilead Sciences, Inc.79.65% $1.74 $48.2B -
What do Analysts Say About NVS or GILD?
Novartis AG has a consensus price target of $153.27, signalling downside risk potential of -2.36%. On the other hand Gilead Sciences, Inc. has an analysts' consensus of $157.43 which suggests that it could grow by 12.68%. Given that Gilead Sciences, Inc. has higher upside potential than Novartis AG, analysts believe Gilead Sciences, Inc. is more attractive than Novartis AG.
Company Buy Ratings Hold Ratings Sell Ratings NVSNovartis AG2 5 2 GILDGilead Sciences, Inc.18 8 0 -
Is NVS or GILD More Risky?
Novartis AG has a beta of 0.523, which suggesting that the stock is 47.695% less volatile than S&P 500. In comparison Gilead Sciences, Inc. has a beta of 0.386, suggesting its less volatile than the S&P 500 by 61.417%.
-
Which is a Better Dividend Stock NVS or GILD?
Novartis AG has a quarterly dividend of $4.74 per share corresponding to a yield of 3.1%. Gilead Sciences, Inc. offers a yield of 2.29% to investors and pays a quarterly dividend of $0.82 per share. Novartis AG pays 42.5% of its earnings as a dividend. Gilead Sciences, Inc. pays out 46.6% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios NVS or GILD?
Novartis AG quarterly revenues are $13.3B, which are larger than Gilead Sciences, Inc. quarterly revenues of $8B. Novartis AG's net income of $2.4B is higher than Gilead Sciences, Inc.'s net income of $2.2B. Notably, Novartis AG's price-to-earnings ratio is 21.44x while Gilead Sciences, Inc.'s PE ratio is 20.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 5.49x versus 5.93x for Gilead Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NVSNovartis AG5.49x 21.44x $13.3B $2.4B GILDGilead Sciences, Inc.5.93x 20.51x $8B $2.2B
-
Which has Higher Returns NVS or RHHBY?
Roche Holding AG has a net margin of 18.03% compared to Novartis AG's net margin of --. Novartis AG's return on equity of 32.47% beat Roche Holding AG's return on equity of 28.65%.
Company Gross Margin Earnings Per Share Invested Capital NVSNovartis AG73.44% $1.25 $81.9B RHHBYRoche Holding AG-- -- $82.8B -
What do Analysts Say About NVS or RHHBY?
Novartis AG has a consensus price target of $153.27, signalling downside risk potential of -2.36%. On the other hand Roche Holding AG has an analysts' consensus of $55.10 which suggests that it could grow by 10.53%. Given that Roche Holding AG has higher upside potential than Novartis AG, analysts believe Roche Holding AG is more attractive than Novartis AG.
Company Buy Ratings Hold Ratings Sell Ratings NVSNovartis AG2 5 2 RHHBYRoche Holding AG2 4 1 -
Is NVS or RHHBY More Risky?
Novartis AG has a beta of 0.523, which suggesting that the stock is 47.695% less volatile than S&P 500. In comparison Roche Holding AG has a beta of 0.507, suggesting its less volatile than the S&P 500 by 49.273%.
-
Which is a Better Dividend Stock NVS or RHHBY?
Novartis AG has a quarterly dividend of $4.74 per share corresponding to a yield of 3.1%. Roche Holding AG offers a yield of 3.23% to investors and pays a quarterly dividend of $1.59 per share. Novartis AG pays 42.5% of its earnings as a dividend. Roche Holding AG pays out 41.09% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios NVS or RHHBY?
Novartis AG quarterly revenues are $13.3B, which are larger than Roche Holding AG quarterly revenues of --. Novartis AG's net income of $2.4B is higher than Roche Holding AG's net income of --. Notably, Novartis AG's price-to-earnings ratio is 21.44x while Roche Holding AG's PE ratio is 20.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 5.49x versus 4.27x for Roche Holding AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NVSNovartis AG5.49x 21.44x $13.3B $2.4B RHHBYRoche Holding AG4.27x 20.52x -- --
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 5
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 4
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 4
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
